Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum K10
- Development stage
- Preclinical
- Lead developer
- SynbioTech Biotechnology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum K10 is a specific probiotic bacterial strain being investigated as an anti-obesity live biotherapeutic candidate. Publicly available literature and patent material describe this strain as having **in vitro** inhibitory activity against digestive enzymes linked to carbohydrate and fat absorption, including alpha-amylase, alpha-glucosidase, and pancreatic lipase, and as reducing adipocyte differentiation in 3T3-L1 cells; in a high-fat-diet animal model it was reported to reduce body weight and fat mass and improve gut permeability. The available evidence appears to be preclinical rather than clinical, and the asset is best characterized as a strain-specific probiotic or microbial therapy rather than an approved pharmaceutical drug. A Korean patent describes the anti-obesity strain and gives accession number KCTC13376BP, and the published work is associated with Korea Food Research Institute and Holzapfel Effective Microbes.
- Other names
- L. plantarum K10
02
Targets
AMY (Pancreatic alpha-amylase)Sucrase-IsomaltaseGehA (Triacylglycerol lipase GehA)PNLIP (Pancreatic triacylglycerol lipase)
Beyond the preview
Go deeper on Lactobacillus plantarum K10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum K10.